Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism.
Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism.
复制标题
慢性血液透析患者用高剂量碳酸钙替代氢氧化铝：高铝血症消失，甲状旁腺功能亢进得到同等控制。
DOI：
--
复制
发表时间：
1983
期刊：
影响因子：
--
通讯作者：
A. Fournier
中科院分区：
文献类型：
--
作者：
P. Morinière;A. Roussel;Y. Tahiri;J. de Frémont;G. Maurel;M. Jaudon;J. Guéris;A. Fournier
26名慢性血液透析患者停用氢氧化铝，8名患者停用维生素D代谢物。口服碳酸钙由4+/-3递增至10+/-5g/d，使血浆PO4<6.0 mg/dl，P<10.5 mg/dl。有3例患者因腹泻和/或失控的高磷酸盐血症而不得不停止这种治疗。在其余患者中，高磷血症和甲状旁腺素的控制情况一样好，甚至更好。高铝血症在大多数患者中消失，说明口服Al(OH)3在诱发高铝血症中的作用。由于两名患者经常出现一过性高钙血症和血管钙化，建议仅在高铝血症患者停用氢氧化铝后再使用大剂量碳酸钙。
Al(OH)3 was discontinued in 26 patients on chronic haemodialysis as well as vitamin D metabolites in eight. Oral CaCO3 was progressively increased from 4 +/- 3 to 10 +/- 5g/d to keep plasma PO4 less than 6.0mg/dl and P Ca less than 10.5mg/dl. This treatment had to be discontinued in three cases because of diarrhoea and/or uncontrolled hyperphosphataemia. In the remaining patients the control of hyperphosphataemia and of PTH values was as good or even better. Hyperaluminaemia disappeared in most patients demonstrating the role of oral Al(OH)3 in the induction of hyperaluminaemia. Because of frequent transient hypercalcaemia and of the occurrence of vascular calcification in two patients, high doses of CaCO3 after discontinuation of Al(OH)3 are advised only in cases of hyperaluminaemia.